Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0003 (-75.00%)
Jul 30, 2026, 4:00 PM EST

Syros Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
0.399.9414.8823.4915.091.98
Revenue Growth
-95.61%-33.23%-36.65%55.62%661.50%-3.32%
Gross Profit
-88.25-98.22-97.0623.4915.091.98
Operating Income
-111.52-126.5-126.36-99.42-82.3-77.74
Net Income
-97.82-164.57-94.65-86.56-84.04-75.44
Earnings Per Share
-2.66-5.81-7.49-13.84-18.25-18.76
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash & Investments
58.28139.53202.3143.41173.9891.42
Total Debt
60.2362.0863.5765.1966.2125.92
Net Cash (Debt)
-1.9577.45138.7378.22107.7765.5
Net Cash Growth
--44.17%77.37%-27.42%64.54%-34.27%
Net Cash Per Share
-0.052.7310.9812.5123.4016.28

Cash Flow & CapEx

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Operating Cash Flow
-100.02-109.71-123.07-99.54-57.36-60.25
Capital Expenditures
-0.04-0.27-1.24-1.25-3.34-12.64
Free Cash Flow
-100.05-109.98-124.31-100.79-60.7-72.89
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Gross Margin
---100.00%100.00%100.00%
Operating Margin
-28891.71%-1273.14%-849.21%-423.28%-545.27%-3922.35%
Pretax Margin
-25340.67%-1656.34%-636.12%-368.52%-556.80%-3806.16%
Profit Margin
-25340.67%-1656.34%-636.12%-368.52%-556.80%-3806.15%
FCF Margin
-25920.72%-1106.87%-835.39%-429.09%-402.17%-3677.65%

Valuation

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingJul '26 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
PS Ratio
0.0120.394.888.6032.93147.97